

Xolair (omalizumab) Non-Oncology Treatment Order Set

1. Patient Name:		
2. DOB:	Height (inches):	Weight (lbs):
3. Diagnosis:		
[] J45.51 Severe persistent asthma with (acute) exacerbat	ion [] J45.41 Moderate pers	istent asthma with (acute) exacerbation
[] J45.50 Severe persistent asthma, uncomplicated	[] J45.40 Moderate pers	istent asthma, uncomplicated
[] J45.52 severe persistent asthma with status asthmaticu	s [] J45.42 Moderate pers	istent asthma with status asthmaticus
[] Other ICD-10 Code: Diagnosis	s description:	
HOACNY will obtain authorization for drug administration prior to this medication not being in alignment with the insurance pla administer the medication.		
4. Pre-medications:		
[] Acetaminophen:		
[] 1000mg PO [] 500mg PO		
[] Diphenhydramine:		
[ ] 25mg PO [ ] 50mg PO [ ] 25	img IV [] 50mg IV	
[] Hydrocortisone: 100mg IVP		
[ ] Other Pre-medication:		
<ul> <li>[] No Pre-medications indicated</li> </ul>		
-	/biosimilar	
5. Drug Order: Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions:	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose	[] 375mg/dose [] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic [] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions: [] New to Therapy	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose	[] 225mg/dose [] 300mg/dose
[] Subcutaneously Every 2 weeks: [] 22 [] Subcutaneously Every 4 weeks: [] 75 Special Instructions:	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & a per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in a reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie         6. Infusion Lab Requirements:         [] CBC with differential annually	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Da administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & comper the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the complications associated with drug administration as well as drug specifie         6. Infusion Lab Requirements:	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Da administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & coper the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie         6. Infusion Lab Requirements:         [] CBC with differential annually         [] Other:         [] No labs monitoring         HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIN	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Do Next Do administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & of per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie         6. Infusion Lab Requirements:         [] CBC with differential annually         [] Other:         [] No labs monitoring         HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIN         The prescribing physician is responsible for ordering, obtaining, reviewing	5mg/dose [] 300mg/dose mg/dose [] 150mg/dose Next Do Next Do administration, post-infusion observ condition or delayed adverse events e prescribing physician is responsible ic monitoring parameters before pro	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & of per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in the reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifie         6. Infusion Lab Requirements:         [] CBC with differential annually         [] Other:         [] No labs monitoring         HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIN         The prescribing physician is responsible for ordering, obtaining, reviewing	5mg/dose       [] 300mg/dose         img/dose       [] 150mg/dose         img/dose       [] 150mg/dose         mg/dose       [] 150mg/dose         img/dose       [] 150mg/dose	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & a per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in a reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifies.         6. Infusion Lab Requirements:         [] Other:         [] No labs monitoring         HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIT The prescribing physician is responsible for ordering, obtaining, reviewing         7. Baseline Lab/Testing completed:         [] Serum IgE level, date:       [] CE	5mg/dose       [] 300mg/dose         img/dose       [] 150mg/dose         img/dose       [] 150mg/dose         mg/dose       [] 150mg/dose         img/dose       [] 150mg/dose	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & a per the HOACNY Infusion Policy & Procedure Guidelines. Any changes in a reported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifies.         6. Infusion Lab Requirements:         [] CBC with differential annually         [] Other:         [] No labs monitoring         HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMIT The prescribing physician is responsible for ordering, obtaining, reviewing         7. Baseline Lab/Testing completed:         [] Serum IgE level, date:       [] CE	5mg/dose       [] 300mg/dose         img/dose       [] 150mg/dose         img/dose       [] Next Do         administration, post-infusion observents       events         condition or delayed adverse events       events         e prescribing physician is responsible       is responsible         is monitoring parameters before produce       monitoring parameters before produce         INISTRATION.       g all laboratory results & providing co         3C, date:       [] Oth	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received         HOA of CNY is responsible to provide nursing care, safe drug handling & comported to the prescribing physician for evaluation & management. The complications associated with drug administration as well as drug specifies. Any changes in the complications associated with drug administration as well as drug specifies.         6. Infusion Lab Requirements:         [] CBC with differential annually         [] Other:         [] No labs monitoring         HOA of CNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADM.         The prescribing physician is responsible for ordering, obtaining, reviewing         7. Baseline Lab/Testing completed:         [] Serum IgE level, date:       [] CE         8. Patient Assistance & REMS Program Enrollment	5mg/dose       [] 300mg/dose         img/dose       [] 150mg/dose         img/dose       [] Next Do         administration, post-infusion observ         condition or delayed adverse events         prescribing physician is responsible         ic monitoring parameters before pro         INISTRATION.         g all laboratory results & providing c         3C, date:       [] Oth         program.	[] 225mg/dose [] 300mg/dose
Xolair (omalizumab) Ok to substitute with generic         [] Subcutaneously Every 2 weeks: [] 22         [] Subcutaneously Every 4 weeks: [] 75         Special Instructions:         [] New to Therapy         [] Continuing therapy: Last Dose Received	5mg/dose       [] 300mg/dose         img/dose       [] 150mg/dose         img/dose       [] Next Do         administration, post-infusion observ       condition or delayed adverse events         prescribing physician is responsible       is responsible         ic monitoring parameters before produce       [] Oth         INISTRATION.       [] Oth         3C, date:       [] Oth         program.         ams.	[] 225mg/dose [] 300mg/dose